Scientists rely on high-throughput screening tools to identify promising small-molecule compounds for the development of biochemical probes and drugs. This study focuses on the identification of promiscuous bioactive compounds, which are compounds that appear active in many high-throughput screening experiments against diverse targets but are often false-positives which may not be easily developed into successful probes. These compounds can exhibit bioactivity due to nonspecific, intractable mechanisms of action and/or by interference with specific assay technology readouts. Such “frequent hitters” are now commonly identified using substructure filters, including pan assay interference compounds (PAINS). Herein, we show that mechanistic mod...
This article describes a set of 275 rules, developed over an 18-year period, used to identify compou...
This article describes a set of 275 rules, developed over an 18-year period, used to identify compou...
The most desirable compound leads from high-throughput assays are those with novel biological activi...
This study presents an analysis of the small molecule bioactivity profiles across large quantities o...
This study presents an analysis of the small molecule bioactivity profiles across large quantities o...
This study presents an analysis of the small molecule bioactivity profiles across large quantities o...
Assay interference compounds give rise to false-positives and cause substantial problems in medicina...
Assay interference caused by small molecules continues to pose a significant challenge for early dru...
To develop more effective therapies to treat human diseases, a better method of finding the biologic...
Assay interference caused by small molecules continues to pose a significant challenge for early dru...
Drug discovery is no longer relying on the one gene-one disease paradigm nor on target-based screeni...
Compounds with apparent activity in a variety of assays might disable target proteins or produce fal...
The ability of compounds to interact with multiple targets is also referred to as promiscuity. Multi...
In this dissertation, I present several strategies to leverage experimental data towards a quantitat...
In this dissertation, I present several strategies to leverage experimental data towards a quantitat...
This article describes a set of 275 rules, developed over an 18-year period, used to identify compou...
This article describes a set of 275 rules, developed over an 18-year period, used to identify compou...
The most desirable compound leads from high-throughput assays are those with novel biological activi...
This study presents an analysis of the small molecule bioactivity profiles across large quantities o...
This study presents an analysis of the small molecule bioactivity profiles across large quantities o...
This study presents an analysis of the small molecule bioactivity profiles across large quantities o...
Assay interference compounds give rise to false-positives and cause substantial problems in medicina...
Assay interference caused by small molecules continues to pose a significant challenge for early dru...
To develop more effective therapies to treat human diseases, a better method of finding the biologic...
Assay interference caused by small molecules continues to pose a significant challenge for early dru...
Drug discovery is no longer relying on the one gene-one disease paradigm nor on target-based screeni...
Compounds with apparent activity in a variety of assays might disable target proteins or produce fal...
The ability of compounds to interact with multiple targets is also referred to as promiscuity. Multi...
In this dissertation, I present several strategies to leverage experimental data towards a quantitat...
In this dissertation, I present several strategies to leverage experimental data towards a quantitat...
This article describes a set of 275 rules, developed over an 18-year period, used to identify compou...
This article describes a set of 275 rules, developed over an 18-year period, used to identify compou...
The most desirable compound leads from high-throughput assays are those with novel biological activi...